Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Gabapentin to reduce pain in women aged between 18 and 50 years with chronic pelvic pain: the GaPP2 RCT›References

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Gabapentin to reduce pain in women aged between 18 and 50 years with chronic pelvic pain: the GaPP2 RCT · References

References

CC BY 4.0 · NIHR Journals Library · approximately 11 min read

  1. Lewis SC, Bhattacharya S, Wu O, Vincent K, Jack SA, Critchley HO, et al. Gabapentin for the Management of Chronic Pelvic Pain in Women (GaPP1): a pilot randomised controlled trial. PLOS ONE 2016;11:e0153037. 10.1371/journal.pone.015303727070434
  2. Zondervan KT, Yudkin PL, Vessey MP, Dawes MG, Barlow DH, Kennedy SH. Prevalence and incidence of chronic pelvic pain in primary care: evidence from a national general practice database. Br J Obstet Gynaecol 1999;106:1149–55. 10.1111/j.1471-0528.1999.tb08140.x10549959
  3. Latthe P, Latthe M, Say L, Gülmezoglu M, Khan KS. WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity. BMC Public Health 2006;6:177. 10.1186/1471-2458-6-17716824213
  4. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287–333. 10.1016/j.ejpain.2005.06.00916095934
  5. Ayorinde AA, Macfarlane GJ, Saraswat L, Bhattacharya S. Chronic pelvic pain in women: an epidemiological perspective. Womens Health 2015;11:851–64. 10.2217/whe.15.30
  6. Cheong Y, William Stones R. Chronic pelvic pain: aetiology and therapy. Best Pract Res Clin Obstet Gynaecol 2006;20:695–711. 10.1016/j.bpobgyn.2006.04.00416765092
  7. Daniels JP, Khan KS. Chronic pelvic pain in women. BMJ 2010;341:c4834. 10.1136/bmj.c483420923840
  8. Tracey I, Mantyh PW. The cerebral signature for pain perception and its modulation. Neuron 2007;55:377–91. 10.1016/j.neuron.2007.07.01217678852
  9. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain 2005;9:463–84. 10.1016/j.ejpain.2004.11.00115979027
  10. Vachon-Presseau E, Roy M, Martel MO, Caron E, Marin MF, Chen J, et al. The stress model of chronic pain: evidence from basal cortisol and hippocampal structure and function in humans. Brain 2013;136:815–27. 10.1093/brain/aws37123436504
  11. Blackburn-Munro G. Hypothalamo-pituitary-adrenal axis dysfunction as a contributory factor to chronic pain and depression. Curr Pain Headache Rep 2004;8:116–24. 10.1007/s11916-004-0025-914980146
  12. Tracey I, Bushnell MC. How neuroimaging studies have challenged us to rethink: is chronic pain a disease? J Pain 2009;10:1113–20. 10.1016/j.jpain.2009.09.00119878862
  13. National Institute for Health and Care Excellence (NICE). Neuropathic Pain – Pharmacological Management. NICE clinical guideline 173. London: NICE; 2013.
  14. Scottish Intercollegiate Guidelines Network (SIGN). SIGN 136. Management of Chronic Pain. Edinburgh: SIGN; 2013.
  15. Horne AW, Critchley HO, Doust A, Fehr D, Wilson J, Wu O, et al. GaPP: a pilot randomised controlled trial of the efficacy of action of gabapentin for the management of chronic pelvic pain in women: study protocol. BMJ Open 2012;2:e001297. 10.1136/bmjopen-2012-001297
  16. Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice AS, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia – an overview of Cochrane reviews. Cochrane Database Syst Rev 2013;11:CD010567. 10.1002/14651858.CD010567.pub2
  17. Horne AW, Vincent K, Cregg R, Daniels J. Is gabapentin effective for women with unexplained chronic pelvic pain? BMJ 2017;358:j3520. 10.1136/bmj.j352028935652
  18. NICE. Endometriosis: Diagnosis and Management. NICE Guideline. 2017. URL: www.nice.org.uk/guidance/ng73 (accessed October 2020).
  19. NICE. Neuropathic Pain in Adults: Pharmacological Management in Non-specialist Settings. Clinical Guideline. 2013. URL: www.nice.org.uk/guidance/cg173 (accessed October 2020).
  20. Sator-Katzenschlager SM, Scharbert G, Kress HG, Frickey N, Ellend A, Gleiss A, Kozek-Langenecker SA. Chronic pelvic pain treated with gabapentin and amitriptyline: a randomized controlled pilot study. Wien Klin Wochenschr 2005;117:761–8. 10.1007/s00508-005-0464-216416358
  21. AbdelHafeez MA, Reda A, Elnaggar A, El-Zeneiny H, Mokhles JM. Gabapentin for the management of chronic pelvic pain in women. Arch Gynecol Obstet 2019;300:1271–7. 10.1007/s00404-019-05272-z31435774
  22. Pontari MA, Krieger JN, Litwin MS, White PC, Anderson RU, McNaughton-Collins M, et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Arch Intern Med 2010;170:1586–93. 10.1001/archinternmed.2010.31920876412
  23. Agarwal MM, Elsi Sy M. Gabapentenoids in pain management in urological chronic pelvic pain syndrome: gabapentin or pregabalin? Neurourol Urodyn 2017;36:2028–33. 10.1002/nau.2322528185319
  24. Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction 2016;111:1160–74. 10.1111/add.1332427265421
  25. Peckham AM, Evoy KE, Covvey JR, Ochs L, Fairman KA, Sclar DA. Predictors of gabapentin overuse with or without concomitant opioids in a commercially insured U.S. population. Pharmacotherapy 2018;38:436–43. 10.1002/phar.209629484686
  26. Evoy KE, Covvey JR, Peckham AM, Ochs L, Hultgren KE. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: an analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS). Res Social Adm Pharm 2019;15:953–8. 10.1016/j.sapharm.2018.06.01831303196
  27. Great Britain. Misuse of Drugs Act 1971. London: The Stationery Office; 1971.
  28. Great Britain. Misuse of Drugs Regulations 2001, UK Statutory Instruments (No. 3998). London: The Stationery Office; 2001.
  29. Molero Y, Larsson H, D’Onofrio BM, Sharp DJ, Fazel S. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. BMJ 2019;365:l2147. 10.1136/bmj.l214731189556
  30. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L. Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol 1997;121:1513–22. 10.1038/sj.bjp.07013209283683
  31. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998;29:233–49. 10.1016/S0920-1211(97)00084-39551785
  32. Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007;28:75–82. 10.1016/j.tips.2006.12.00617222465
  33. Iannetti GD, Zambreanu L, Wise RG, Buchanan TJ, Huggins JP, Smart TS, et al. Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans. Proc Natl Acad Sci USA 2005;102:18195–200. 10.1073/pnas.050662410216330766
  34. Wanigasekera V, Wartolowska K, Huggins JP, Duff EP, Vennart W, Whitlock M, et al. Disambiguating pharmacological mechanisms from placebo in neuropathic pain using functional neuroimaging. Br J Anaesth 2018;120:299–307. 10.1016/j.bja.2017.11.06429406179
  35. Governo RJ, Morris PG, Marsden CA, Chapman V. Gabapentin evoked changes in functional activity in nociceptive regions in the brain of the anaesthetized rat: an fMRI study. Br J Pharmacol 2008;153:1558–67. 10.1038/bjp.2008.2718264121
  36. Harris RE, Napadow V, Huggins JP, Pauer L, Kim J, Hampson J, et al. Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients. Anesthesiology 2013;119:1453–64. 10.1097/ALN.000000000000001724343290
  37. Seretny M, Murray SR, Whitaker L, Murnane J, Whalley H, Pernet C, Horne AW. The use of brain functional magnetic resonance imaging to determine the mechanism of action of gabapentin in managing chronic pelvic pain in women: a pilot study. BMJ Open 2019;9:e026152. 10.1136/bmjopen-2018-026152
  38. Vincent K, Baranowski A, Bhattacharya S, Birch J, Cheong Y, Cregg R, et al. GaPP2, a multicentre randomised controlled trial of the efficacy of gabapentin for the management of chronic pelvic pain in women: study protocol. BMJ Open 2018;8:e014924.
  39. Ware JE, Kosinski M, Keller SD. SF-12: How to Score the SF-12 Physical and Mental Health Summary Scales. Boston, MA: Health Institute, New England Medical Center; 1995.
  40. Cleeland SC. The Brief Pain Inventory User Guide. 2009. URL: www.mdanderson.org/documents/Departments-and-Divisions/Symptom-Research/BPI_UserGuide.pdf (accessed 24 October 2019).
  41. Shahid A, Wilkinson K, Marcu S, Shapiro CM. Brief Fatigue Inventory. In Shahid A, Wilkinson K, Marcu S, Shapiro CM, editors. STOP, THAT and One Hundred Other Sleep Scales. New York, NY, USA: Springer; 2011. 10.1007/978-1-4419-9893-4_11
  42. Goldberg D. Manual of the General Health Questionnaire. Slough: National Foundation for Educational Research; 1978.
  43. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993;4:353–65. 10.2165/00019053-199304050-0000610146874
  44. Sullivan MJ. The Pain Catastrophizing Scale. User Manual. Montreal, QC: McGill University; 2009.
  45. Thirlaway K, Fallowfield L, Cuzick J. The sexual activity questionnaire: a measure of women’s sexual functioning. Qual Life Res 1996;5:81–90. 10.1007/BF004359728901370
  46. Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911–20. 10.1185/030079906X13248817022849
  47. Parsons CL, Dell J, Stanford EJ, Bullen M, Kahn BS, Waxell T, Koziol JA. Increased prevalence of interstitial cystitis: previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium sensitivity. Urology 2002;60:573–8. 10.1016/S0090-4295(02)01829-012385909
  48. Dworkin RH, Turk DC, Peirce-Sandner S, Baron R, Bellamy N, Burke LB, et al. Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain 2010;149:177–93. 10.1016/j.pain.2010.02.01820207481
  49. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585–612. 10.1038/bjc.1976.220795448
  50. Damocles Study Group NHSHTAP. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet 2005;365:711–22. 10.1016/S0140-6736(05)17965-315721478
  51. Horne AW, Vincent K, Hewitt CA, Middleton LJ, Koscielniak M, Szubert W, et al. Gabapentin for chronic pelvic pain in women (GaPP2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2020;396:909–17. 10.1016/S0140-6736(20)31693-732979978
  52. Gwilym SE, Filippini N, Douaud G, Carr AJ, Tracey I. Thalamic atrophy associated with painful osteoarthritis of the hip is reversible after arthroplasty: a longitudinal voxel-based morphometric study. Arthritis Rheum 2010;62:2930–40. 10.1002/art.2758520518076
  53. Kulkarni B, Bentley DE, Elliott R, Julyan PJ, Boger E, Watson A, et al. Arthritic pain is processed in brain areas concerned with emotions and fear. Arthritis Rheum 2007;56:1345–54. 10.1002/art.2246017393440
  54. Soni A, Wanigasekera V, Mezue M, Cooper C, Javaid MK, Price AJ, Tracey I. Central sensitization in knee osteoarthritis: relating presurgical brainstem neuroimaging and PainDETECT-based patient stratification to arthroplasty outcome. Arthritis Rheumatol 2019;71:550–60. 10.1002/art.4074930295432
  55. Gwilym SE, Oag HC, Tracey I, Carr AJ. Evidence that central sensitisation is present in patients with shoulder impingement syndrome and influences the outcome after surgery. J Bone Joint Surg Br 2011;93:498–502. 10.1302/0301-620X.93B4.2505421464489
  56. As-Sanie S, Harris RE, Napadow V, Kim J, Neshewat G, Kairys A, et al. Changes in regional gray matter volume in women with chronic pelvic pain: a voxel-based morphometry study. Pain 2012;153:1006–14. 10.1016/j.pain.2012.01.03222387096
  57. As-Sanie S, Kim J, Schmidt-Wilcke T, Sundgren PC, Clauw DJ, Napadow V, Harris RE. Functional connectivity is associated with altered brain chemistry in women with endometriosis-associated chronic pelvic pain. J Pain 2016;17:1–13. 10.1016/j.jpain.2015.09.00826456676
  58. Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci 2007;27:10000–6. 10.1523/JNEUROSCI.2849-07.200717855614
  59. Wood PB, Schweinhardt P, Jaeger E, Dagher A, Hakyemez H, Rabiner EA, et al. Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci 2007;25:3576–82. 10.1111/j.1460-9568.2007.05623.x17610577
  60. Baliki MN, Chialvo DR, Geha PY, Levy RM, Harden RN, Parrish TB, Apkarian AV. Chronic pain and the emotional brain: specific brain activity associated with spontaneous fluctuations of intensity of chronic back pain. J Neurosci 2006;26:12165–73. 10.1523/JNEUROSCI.3576-06.200617122041
  61. Mayer EA, Berman S, Suyenobu B, Labus J, Mandelkern MA, Naliboff BD, Chang L. Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain 2005;115:398–409. 10.1016/j.pain.2005.03.02315911167
  62. Gündel H, Valet M, Sorg C, Huber D, Zimmer C, Sprenger T, Tölle TR. Altered cerebral response to noxious heat stimulation in patients with somatoform pain disorder. Pain 2008;137:413–21. 10.1016/j.pain.2007.10.00318022320
  63. Brawn J, Morotti M, Zondervan KT, Becker CM, Vincent K. Central changes associated with chronic pelvic pain and endometriosis. Hum Reprod Update 2014;20:737–47. 10.1093/humupd/dmu02524920437
  64. Kaya S, Hermans L, Willems T, Roussel N, Meeus M. Central sensitization in urogynecological chronic pelvic pain: a systematic literature review. Pain Physician 2013;16:291–308.23877446
  65. Wiffen PJ, Derry S, Bell RF, Rice AS, Tölle TR, Phillips T, Moore RA. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017;6:CD007938. 10.1002/14651858.CD007938.pub4
  66. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837–42. 10.1001/jama.280.21.18379846778
  67. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831–6. 10.1001/jama.280.21.18319846777
  68. Hwang JH, Yaksh TL. Effect of subarachnoid gabapentin on tactile-evoked allodynia in a surgically induced neuropathic pain model in the rat. Reg Anesth 1997;22:249–56. 10.1016/s1098-7339(06)80010-69168217
  69. Jones DL, Sorkin LS. Systemic gabapentin and S(+)-3-isobutyl-gamma-aminobutyric acid block secondary hyperalgesia. Brain Res 1998;810:93–9. 10.1016/S0006-8993(98)00890-79813259
  70. Jun JH, Yaksh TL. The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat. Anesth Analg 1998;86:348–54. 10.1097/00000539-199802000-000259459247
  71. Stanfa LC, Singh L, Williams RG, Dickenson AH. Gabapentin, ineffective in normal rats, markedly reduces C-fibre evoked responses after inflammation. Neuroreport 1997;8:587–90. 10.1097/00001756-199702100-000029106728
  72. Rauck R, Coffey RJ, Schultz DM, Wallace MS, Webster LR, McCarville SE, et al. Intrathecal gabapentin to treat chronic intractable noncancer pain. Anesthesiology 2013;119:675–86. 10.1097/ALN.0b013e3182a10fbf23835590
  73. Wanigasekera V, Mezue M, Andersson J, Kong Y, Tracey I. Disambiguating pharmacodynamic efficacy from behavior with neuroimaging: implications for analgesic drug development. Anesthesiology 2016;124:159–68. 10.1097/ALN.000000000000092426669989
  74. Tracey I, Woolf CJ, Andrews NA. Composite pain biomarker signatures for objective assessment and effective treatment. Neuron 2019;101:783–800. 10.1016/j.neuron.2019.02.01930844399
  75. The University of Edinburgh. Edinburgh Imaging Facility QMRI. URL: www.ed.ac.uk/clinical-sciences/edinburgh-imaging/research/facilities-and-equipment/edinburgh-imaging-facilities/edinburgh-imaging-facility-qmri (accessed 13 February 2020).
  76. Brodmann K. Vergleichende Lokalisationslehre der Grosshirnrinde. Leipzig: Johann Ambrosius Barth; 1909.
  77. Lancaster JL, Woldorff MG, Parsons LM, Liotti M, Freitas CS, Rainey L, et al. Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp 2000;10:120–31. 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-810912591
  78. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 2003;19:1233–9. 10.1016/S1053-8119(03)00169-112880848
  79. De Felice M, Ossipov MH. Cortical and subcortical modulation of pain. Pain Manag 2016;6:111–20. 10.2217/pmt.15.6326984039
  80. Porro CA, Baraldi P, Pagnoni G, Serafini M, Facchin P, Maieron M, Nichelli P. Does anticipation of pain affect cortical nociceptive systems? J Neurosci 2002;22:3206–14. 10.1523/JNEUROSCI.22-08-03206.200211943821
  81. Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ, et al. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 2004;303:1162–7. 10.1126/science.109306514976306
  82. Zubieta JK, Bueller JA, Jackson LR, Scott DJ, Xu Y, Koeppe RA, et al. Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci 2005;25:7754–62. 10.1523/JNEUROSCI.0439-05.200516120776
  83. Bannister K, Qu C, Navratilova E, Oyarzo J, Xie JY, King T, et al. Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain. Pain 2017;158:2386–95. 10.1097/j.pain.000000000000104028832395
  84. Gomtsian L, Bannister K, Eyde N, Robles D, Dickenson AH, Porreca F, Navratilova E. Morphine effects within the rodent anterior cingulate cortex and rostral ventromedial medulla reveal separable modulation of affective and sensory qualities of acute or chronic pain. Pain 2018;159:2512–21. 10.1097/j.pain.000000000000135530086115
  85. Shackman AJ, Salomons TV, Slagter HA, Fox AS, Winter JJ, Davidson RJ. The integration of negative affect, pain and cognitive control in the cingulate cortex. Nat Rev Neurosci 2011;12:154–67. 10.1038/nrn299421331082
  86. Etkin A, Egner T, Peraza DM, Kandel ER, Hirsch J. Resolving emotional conflict: a role for the rostral anterior cingulate cortex in modulating activity in the amygdala. Neuron 2006;51:871–82. 10.1016/j.neuron.2006.07.02916982430
  87. Holroyd CB, Yeung N. Motivation of extended behaviors by anterior cingulate cortex. Trends Cogn Sci 2012;16:122–8. 10.1016/j.tics.2011.12.00822226543
  88. Matharu MS, Bartsch T, Ward N, Frackowiak RS, Weiner R, Goadsby PJ. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 2004;127:220–30. 10.1093/brain/awh02214607792
  89. Fulbright RK, Troche CJ, Skudlarski P, Gore JC, Wexler BE. Functional MR imaging of regional brain activation associated with the affective experience of pain. AJR Am J Roentgenol 2001;177:1205–10. 10.2214/ajr.177.5.177120511641204
  90. Iannetti GD, Wise RG. BOLD functional MRI in disease and pharmacological studies: room for improvement? Magn Reson Imaging 2007;25:978–88. 10.1016/j.mri.2007.03.01817499469
  91. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162–73. 10.1016/S1474-4422(14)70251-025575710
  92. Vachon-Presseau E, Berger SE, Abdullah TB, Huang L, Cecchi GA, Griffith JW, et al. Brain and psychological determinants of placebo pill response in chronic pain patients. Nat Commun 2018;9:3397. 10.1038/s41467-018-05859-130209286
  93. Stones RW, Price C. Health services for women with chronic pelvic pain. J R Soc Med 2002;95:531–5. 10.1177/01410768020950110212411615
  94. Bartlett C, Doyal L, Ebrahim S, Davey P, Bachmann M, Egger M, Dieppe P. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess 2005;9(38). 10.3310/hta9380
  95. Moore A, Derry S, Wiffen P. Gabapentin for chronic neuropathic pain. JAMA 2018;319:818–19. 10.1001/jama.2017.2154729486015
← ConclusionsAcknowledgements →

Attribution. Catherine A Hewitt; Katy Vincent; Lee J Middleton; Liana Romaniuk; Magda Koscielniak; Ann M Doust et al. (2020). Gabapentin to reduce pain in women aged between 18 and 50 years with chronic pelvic pain: the GaPP2 RCT. NIHR Journals Library. Copyright © Queen’s Printer and Controller of HMSO 2020. This work was produced by Hewitt et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK. Licensed under CC BY 4.0. NCBI Bookshelf NBK564183. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support